Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019.
“The TCT meeting is an important venue for Cidara to share data that demonstrate the potential advantages of rezafungin for the prevention of invasive fungal infections in blood and marrow transplant patients,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are especially pleased to present new study results providing further evidence that rezafungin has a low risk of drug-drug interactions and a favorable tolerability profile as a once-weekly antifungal prophylactic agent in this vulnerable patient population.”
Invasive fungal infections (IFIs) are a leading cause of morbidity and mortality among immunocompromised patients, particularly those undergoing blood and marrow transplantation. Rezafungin is a novel antifungal echinocandin being developed as a once-weekly therapy for the prevention of IFIs caused by the most common fungal pathogens: Candida, Aspergillus and Pneumocystis. No single agent is approved today to prevent all of these infections, and current prophylaxis regimens often require multiple antifungals, including azole drugs and Bactrim, that are associated with known drug-drug interactions as well as safety and tolerability issues.
The TCT Meeting convenes more than 3,700 attendees to present and discuss recent progress in basic science, translational research and clinical studies in all areas of blood and marrow transplantation and cellular therapy. Rezafungin data will be featured in three poster presentations by Cidara Therapeutics and its collaborators during Poster Session II, taking place on Saturday, February 23, 2019 from 6:45 p.m. – 7:45 p.m. (Central Time) at the George R. Brown Convention Center, Level 3, Hall B. Presentation details are as follows:
Title: No Relevant Pharmacokinetic (PK) Interaction between Rezafungin and Nine Probe Drugs: Results from a Drug-Drug Interaction (DDI) Study
Poster Number: 535
Presenter: V. Ong
Title: Pharmacokinetic-Pharmacodynamic Analyses of Dose Selection for Rezafungin Prophylaxis Against Invasive Fungal Infections in Bone Marrow Transplantation
Poster Number: 537
Presenter: W. Brown
Title: Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia
Poster Number: 549
Presenter: M. Cushion
All three posters will be on display from 9:00 a.m. until 5:00 p.m. (Central Time) on Saturday, February 23. Copies of the posters will be available on the Cidara website following the meeting: www.cidara.com.
Rezafungin is a novel echinocandin antifungal being developed as a once-weekly therapy to address significant unmet needs in the treatment of candidemia and invasive candidiasis as well as for prophylaxis of invasive fungal infections due to the common fungal pathogens Candida, Aspergillus and Pneumocystis. Cidara’s Phase 3 ReSTORE clinical trial for treatment of candidemia and invasive candidiasis is underway and Cidara plans to commence the Phase 3 ReSPECT prophylaxis clinical trial of rezafungin in patients undergoing allogeneic blood and marrow transplantation in the first quarter of 2019.
About Invasive Fungal Infections
Approximately 97,000 Americans die from hospital-related invasive fungal infections each year. Approximately 90 percent of all reported fungal related deaths result from a few common fungi, including Candida, Aspergillus and Pneumocystis. Systemic fungal infections typically affect patients whose immune systems have been compromised, such as the severely ill and those undergoing organ or blood and marrow transplantation or chemotherapy, including patients with hematologic malignancies.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and plans to initiate a second Phase 3 trial in the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplants. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Cidara also is leveraging its novel Cloudbreak® platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the initiation of rezafungin Phase 3 pivotal trials, the potential for rezafungin to be a novel treatment and prophylactic agent against deadly invasive fungal infections, and rezafungin’s potential for expanded utility across patient settings. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Business Wire source: